Who is sponsoring NCT07231705?

NCT07231705 is sponsored by Kate Farms Inc.

What drugs are being tested in NCT07231705?

Interventions in NCT07231705: Kate Farms Standard 1.2 or Peptide 1.0.

What condition does NCT07231705 study?

NCT07231705 studies Formula Dependent Children 1 to 2 Years of Age.

Is NCT07231705 still recruiting?

NCT07231705 is currently recruiting now. Last updated 14 April 2026.

Last reviewed 2026-04-14 · How we verify

NCT07231705

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Growth and Tolerance of Plant-based Enteral Formulas in Children Ages 12-17 Months.

Recruiting now NA Last updated 14 April 2026

What this trial tests

NA trial testing Kate Farms Standard 1.2 or Peptide 1.0 in Formula Dependent Children 1 to 2 Years of Age in 40 participants. Currently enrolling.

Timeline

13 March 2026

Primary endpoint
31 December 2027

31 March 2028

Quick facts

Lead sponsor	Kate Farms Inc
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	13 March 2026
Primary completion	31 December 2027
Estimated completion	31 March 2028
Sites	1 location across United States

Drugs / interventions tested

Kate Farms Standard 1.2 or Peptide 1.0

Conditions studied

Formula Dependent Children 1 to 2 Years of Age — all drugs for Formula Dependent Children 1 to 2 Years of Age →

Sponsor

Kate Farms Inc — full company profile →

Who can join

Adults 12 Months to 17 Months, any sex, with Formula Dependent Children 1 to 2 Years of Age. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this prospective study is to evaluate the growth and enteral tolerance of two pea protein-based formulas from Kate Farms in children aged 12 to 17 months who are expected to meet most of their nutritional needs through formula. It is hypothesized that the Pediatric Standard 1.2 and Pediatric Peptide 1.0 formulas will support healthy growth in children between 1 and 2 years of age. The study will assess the impact of these formulas on growth, tolerance, body composition, micronutrient levels, and gut microbiome health in tube-fed children. Formula will be provided for 24 weeks.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Kate Farms Inc trials

Trials by the same sponsor.

NCT07234825 — Trial of Partial Enteral Nutrition With Dairy Free Diet in Eosinophilic Esophagitis · NA · recruiting
NCT07096739 — Tolerance of a High Protein Nutrition Shake in Individuals on GLP-1 · NA · completed
NCT07113431 — Partial-enteral Nutrition Protocol for Crohn's Disease · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07231705 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kate Farms Inc
Last refreshed: 14 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07231705.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing